查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462774

到 2030 年癌症疫苗药物管道市场预测：按类型、癌症类型、技术、最终用户和地区进行的全球分析

Cancer Vaccines Drug Pipeline Market Forecasts to 2030 - Global Analysis By Type, Cancer Type,Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球癌症疫苗药物管道市场规模为 64.6 亿美元，预计在预测期内将以 20.0% 的复合年增长率增长，到 2030 年达到 231.7 亿美元。

癌症疫苗药物管道是指专注于创造疫苗来预防、治疗和管理癌症的研究和开发。这些疫苗透过刺激人体的免疫系统识别和攻击癌细胞来发挥作用，有可能提供一种有针对性的、侵入性较小的癌症治疗方法。该管道包括从早期临床前研究到临床试验的各个开发阶段，最终目标是将安全有效的癌症疫苗推向市场。

据世界卫生组织 (WHO) 称，癌症是全球第二大死亡原因，2018 年估计有 960 万人死亡。

癌症发生率上升

随着越来越多的人面临癌症的威胁，对疫苗等有效预防和治疗解决方案的需求正在迅速增加。这种迫切性刺激了研究和开发工作，推动科学家探索、创新和改进疫苗技术，最终扩大研发管道，帮助应对这一日益严峻的全球健康挑战。因此，这些因素正在加速市场的成长。

复杂的开发流程

许多正在研发的癌症疫苗在临床试验中显示出有限的功效，引发了人们对其预防和治疗癌症有效性的担忧。此外，对潜在副作用和免疫反应的安全疑虑导致患者和医疗保健专业人员犹豫不决。如此复杂的流程阻碍了一些公司进入市场，并阻碍了管道的整体发展和多元化。

联合治疗

将癌症疫苗与化疗、免疫疗法和分子标靶疗法等其他既定治疗方法相结合，为彻底改变癌症治疗和改善患者预后提供了独特的机会。这种方法有可能改善治疗结果、最大限度地减少副作用并延长患者的生存期。透过利用各种治疗方法的互补作用机制，组合策略解决了癌症的多方面性质，并在持续对抗这种复杂疾病的过程中提供更有效和个性化的方法，我们的目标是为新的治疗方法舖平道路。

监管障碍

严格的监管要求，包括冗长的核准流程和复杂的临床试验通讯协定，可能会延迟市场进入并增加开发成本。不断变化的监管指南和严格的安全标准的不确定性可能会限制对癌症疫苗研发的投资。此外，不同地区和司法管辖区不同的监管标准可能会使市场状况更加复杂，并限制我们进入全球市场。

COVID-19 的影响

COVID-19 大流行转移了癌症研究和开发的资源、注意力和资金，减缓了疫苗发现和临床试验的进展。封锁措施扰乱了供应链，停止了临床试验，并减缓了潜在癌症疫苗的进展。儘管遇到这些挫折，疫情仍然刺激了疫苗开发的创新和合作，从而加速了远端医疗和远距临床试验监测的采用。

预计预防性疫苗领域在预测期内将是最大的。

预计预防性疫苗产业将占据最大份额。预防性疫苗的重点是透过针对已知会导致某些类型癌症的特定感染因子来预防癌症的发展。这些疫苗的作用是刺激免疫系统识别和消灭与癌症发展相关的病原体，例如病毒和细菌。此外，透过预防这些致癌性病原体的感染，预防性疫苗旨在降低相关癌症的风险。

预计肺癌领域在预测期内复合年增长率最高

预计肺癌领域在预测期内将出现良好的成长。该领域专注于开发专门用于预防或治疗肺癌的疫苗。这些疫苗针对肺癌细胞上的抗原，旨在触发人体针对癌细胞的免疫反应。肺癌是一个重要的全球健康议题，开发有效的疫苗有望减轻肺癌的负担，并提高病患的存活率。

比最大的地区

由于癌症盛行率上升以及人们认识的提高和预防措施的采用增加，亚太地区在预测期内占据了最大的市场占有率。由于人口众多、生技产业的成长以及有利的监管政策，中国成为最大的市场。许多亚洲国家的法律规范变得更加精简和高效，促进了新癌症疫苗的开发和核准。此外，该地区各国政府积极支持癌症研究和开发，包括资助疫苗开发和临床试验。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。北美的癌症负担很高，全部区域流行多种类型的癌症。因此，对有效的预防和治疗方法的需求日益增长。该地区也是积极致力于开发创新癌症疫苗的主要研究机构、製药公司和生物技术公司的所在地。政府机构和私人投资者都为癌症研究和开发（包括疫苗计画）的资金筹措做出了重大贡献。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球癌症疫苗药物管道市场：按类型

  • 预防性疫苗
  • 治疗性疫苗

第六章全球癌症疫苗药物管道市场：依癌症类型分类

  • 乳癌
  • 摄护腺癌
  • 肺癌
  • 大肠直肠癌
  • 其他癌症类型

第七章全球癌症疫苗药物管道市场：依技术分类

  • 重组疫苗
  • 病毒载体疫苗
  • 全细胞疫苗
  • DNA疫苗
  • 其他技术

第八章全球癌症疫苗药物管道市场：依最终用户分类

  • 医院
  • 门诊治疗中心

第九章全球癌症疫苗药物管道市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • AstraZeneca
  • F. Hoffmann-La Roche
  • Merck & Co.
  • Pfizer
  • Johnson & Johnson
  • Sanofi
  • GlaxoSmithKline（GSK）
  • Moderna
  • Novartis
  • Bristol-Myers Squibb
  • BioNTech
  • Genentech
  • Bavarian Nordic
  • Takeda Pharmaceuticals
  • OncoGenex Pharmaceuticals
  • Northwest Biotherapeutics
  • Vaxil Bio
  • Immunomic Therapeutics
  • Transgene
  • Arbor Pharmaceuticals
Product Code: SMRC25825

According to Stratistics MRC, the Global Cancer Vaccines Drug Pipeline Market is accounted for $6.46 billion in 2023 and is expected to reach $23.17 billion by 2030 growing at a CAGR of 20.0% during the forecast period. The Cancer Vaccines Drug Pipeline is the ongoing research and development efforts focused on creating vaccines for preventing, treating, or managing cancer. These vaccines work by stimulating the body's immune system to recognize and attack cancer cells, offering a potentially targeted and less invasive approach to cancer treatment. The pipeline includes various stages of development, from early preclinical research to clinical trials, with the ultimate goal of bringing safe and effective cancer vaccines to market.

According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018.

Market Dynamics:

Driver:

Rising incidence of cancer

As more individuals face the threat of cancer, the demand for effective preventative and therapeutic solutions like vaccines surges. This urgency incentivizes research and development efforts, pushing scientists to explore, innovate, and refine vaccine technologies, ultimately expanding the pipeline with the hope of combating this growing global health challenge. Therefore, these factors are accelerating market growth.

Restraint:

Complex development process

Many cancer vaccines in the pipeline demonstrate limited efficacy in clinical trials, raising concerns about their effectiveness in preventing or treating cancer. Also, safety concerns regarding potential side effects and immune reactions can create hesitancy among patients and healthcare professionals. The complex process discourages some companies from entering the market, hindering the overall development and diversification of the pipeline.

Opportunity:

Combination therapies

Integrating cancer vaccines with other established therapies, such as chemotherapy, immunotherapy, or targeted therapies, presents a unique opportunity to revolutionize cancer treatment and improve patient outcomes. This approach holds promise for improving treatment outcomes, minimising adverse effects, and potentially extending patient survival. By leveraging the complementary mechanisms of action of various therapies, combination strategies aim to address the multifaceted nature of cancer, paving the way for more effective and personalised treatment approaches in the ongoing battle against this complex disease.

Threat:

Regulatory hurdles

Stringent regulatory requirements, including lengthy approval processes and complex clinical trial protocols, can delay market entry and increase development costs. Uncertainty surrounding evolving regulatory guidelines and stringent safety standards may deter investment in cancer vaccine research and development. Also, varying regulatory standards across different regions and jurisdictions further complicate the market landscape, potentially limiting global market access.

Covid-19 Impact

The COVID-19 pandemic has diverted resources, attention, and funding away from cancer research and development, slowing down progress in vaccine discovery and clinical trials. Lockdown measures disrupted supply chains and halted clinical trials, delaying the advancement of potential cancer vaccines. Despite these setbacks, the pandemic has also spurred innovation and collaboration in vaccine development, leading to the accelerated adoption of telemedicine and remote clinical trial monitoring, which may benefit the cancer vaccine pipeline market in the long term.

The prophylactic vaccine segment is expected to be the largest during the forecast period

The prophylactic vaccine segment is estimated to hold the largest share. The prophylactic vaccine focuses on preventing the development of cancer by targeting specific infectious agents known to cause certain types of cancer. These vaccines work by stimulating the immune system to recognise and destroy pathogens, such as viruses or bacteria that are linked to cancer development. Moreover, by preventing infection with these carcinogenic agents, prophylactic vaccines aim to reduce the risk of developing associated cancers.

The lung cancer segment is expected to have the highest CAGR during the forecast period

The lung cancer segment is anticipated to have lucrative growth during the forecast period. This segment focuses on the development of vaccines specifically designed to prevent or treat lung cancer. These vaccines target antigens present in lung cancer cells, aiming to trigger the body's immune response against tumour cells. With lung cancer being a significant global health concern, the development of effective vaccines holds promise for reducing its burden and improving patient survival rates.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the rising prevalence of cancer in the region, coupled with increasing awareness and adoption of preventive measures. China is the largest market, driven by its large population, growing biotechnology sector, and favourable regulatory policies. Regulatory frameworks in many Asian countries are becoming more streamlined and efficient, facilitating the development and approval of new cancer vaccines. Moreover, governments in the region are actively supporting cancer research and development, including funding for vaccine development and clinical trials.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America faces a significant burden of cancer, with several types prevalent across the region. This drives demand for effective preventive and therapeutic options. Also, the region boasts leading research institutions, pharmaceutical companies, and biotechnology firms actively engaged in developing innovative cancer vaccines. Both government agencies and private investors significantly contribute to funding cancer research and development, including vaccine programs.

Key players in the market

Some of the key players in the Cancer Vaccines Drug Pipeline Market include AstraZeneca, F. Hoffmann-La Roche, Merck & Co., Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline (GSK), Moderna, Novartis, Bristol-Myers Squibb, BioNTech, Genentech, Bavarian Nordic, Takeda Pharmaceuticals, OncoGenex Pharmaceuticals, Northwest Biotherapeutics, Vaxil Bio, Immunomic Therapeutics, Transgene and Arbor Pharmaceuticals.

Key Developments:

In February 2024, AstraZeneca unveils successes in treatment of lung cancer, with its leading drug slowing progression of the disease at an early stage. AstraZeneca also announced that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free survival by almost nine months.

In December 2023, AstraZeneca ties up with AI Biologics Company to develop cancer drug. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy - a leading focus of Anglo-Swedish drugmaker AstraZeneca.

Types Covered:

  • Prophylactic Vaccine
  • Therapeutic Vaccine

Cancer Types Covered:

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Cancer Types

Technologies Covered:

  • Recombinant Vaccines
  • Viral Vector Vaccines
  • Whole-Cell Vaccines
  • DNA Vaccines
  • Other Technologies

End Users Covered:

  • Hospital
  • Ambulatory Care Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Vaccines Drug Pipeline Market, By Type

  • 5.1 Introduction
  • 5.2 Prophylactic Vaccine
  • 5.3 Therapeutic Vaccine

6 Global Cancer Vaccines Drug Pipeline Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Prostate Cancer
  • 6.4 Lung Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Other Cancer Types

7 Global Cancer Vaccines Drug Pipeline Market, By Technology

  • 7.1 Introduction
  • 7.2 Recombinant Vaccines
  • 7.3 Viral Vector Vaccines
  • 7.4 Whole-Cell Vaccines
  • 7.5 DNA Vaccines
  • 7.6 Other Technologies

8 Global Cancer Vaccines Drug Pipeline Market, By End User

  • 8.1 Introduction
  • 8.2 Hospital
  • 8.3 Ambulatory Care Centers

9 Global Cancer Vaccines Drug Pipeline Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AstraZeneca
  • 11.2 F. Hoffmann-La Roche
  • 11.3 Merck & Co.
  • 11.4 Pfizer
  • 11.5 Johnson & Johnson
  • 11.6 Sanofi
  • 11.7 GlaxoSmithKline (GSK)
  • 11.8 Moderna
  • 11.9 Novartis
  • 11.10 Bristol-Myers Squibb
  • 11.11 BioNTech
  • 11.12 Genentech
  • 11.13 Bavarian Nordic
  • 11.14 Takeda Pharmaceuticals
  • 11.15 OncoGenex Pharmaceuticals
  • 11.16 Northwest Biotherapeutics
  • 11.17 Vaxil Bio
  • 11.18 Immunomic Therapeutics
  • 11.19 Transgene
  • 11.20 Arbor Pharmaceuticals

List of Tables

  • Table 1 Global Cancer Vaccines Drug Pipeline Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 4 Global Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 5 Global Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 6 Global Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 7 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 8 Global Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 9 Global Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 10 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 11 Global Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 12 Global Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 13 Global Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 14 Global Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 15 Global Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 16 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 17 Global Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 19 Global Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 20 North America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 22 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 23 North America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 24 North America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 25 North America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 26 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 27 North America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 28 North America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 29 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 30 North America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 32 North America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 33 North America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 34 North America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 35 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 36 North America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 38 North America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 39 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 41 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 42 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 43 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 44 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 45 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 46 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 47 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 48 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 49 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 50 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 51 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 52 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 53 Europe Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 54 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 55 Europe Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 56 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 57 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 58 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 61 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 62 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 63 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 64 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 65 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 66 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 67 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 68 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 69 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 70 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 71 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 72 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 73 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 74 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 76 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 77 South America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 79 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 80 South America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 81 South America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 82 South America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 83 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 84 South America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 85 South America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 86 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 87 South America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 88 South America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 89 South America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 90 South America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 91 South America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 92 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 93 South America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 South America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 95 South America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 96 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 99 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 100 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 101 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 102 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 103 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 104 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 105 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 106 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 107 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 108 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 109 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 110 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 111 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 112 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 114 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)